Skip to content
About
Management
Board of Directors
Scientific Advisory Board
Therapeutic Areas
Pipeline
OLX07010 in Rare Tauopathies
OLX07010 Alzheimer’s
Technology
MOA
Patents
News & Publications
Partners and Collaborators
Contact Us
Menu
Oligomerix Announces First-in-Human Dosing of Tau Self-Association Inhibitor OLX-07010
Home
>
News
>
Oligomerix Announces First-in-Human Dosing of Tau Self-Association Inhibitor OLX-07010
Print
Oligomerix
>
News
>
Breaking News
Category:
Breaking News
Oligomerix Announces First-in-Human Dosing of Tau Self-Association Inhibitor OLX-07010
Scroll to top
close ×
